Madrigal Pharmaceuticals
MDGL
82 hedge funds and large institutions have $213M invested in Madrigal Pharmaceuticals in 2014 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 36 increasing their positions, 20 reducing their positions, and 9 closing their positions.
80% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 20
22% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 9
3% more funds holding
Funds holding: 80 → 82 (+2)
0% more capital invested
Capital invested by funds: $212M → $213M (+$864K)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
55% less call options, than puts
Call options by funds: $1.53M | Put options by funds: $3.39M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Caxton Corporation
Princeton,
New Jersey
|
+$5.23M |
| 2 |
D.E. Shaw & Co
New York
|
+$4.03M |
| 3 |
New York State Common Retirement Fund
Albany,
New York
|
+$891K |
| 4 |
SIP
Stoneridge Investment Partners
Radnor,
Pennsylvania
|
+$883K |
| 5 |
SG Americas Securities
New York
|
+$707K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$1.3M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.11M |
| 3 |
OWIM
Old West Investment Management
Los Angeles,
California
|
-$301K |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$269K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$227K |
MDGL Hedge Fund Activity: Q2 2014 in Review
82 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in Madrigal Pharmaceuticals (MDGL) for Q2 2014, worth a combined $213M — up 0.41% from $212M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new MDGL positions and 9 closed out — a net gain of 2 holders — while 36 added to existing stakes and 20 trimmed.
The largest buyer was Caxton Corporation, adding an estimated $5.23M. The largest seller was Jennison Associates, cutting an estimated $1.3M.
- 82 institutional investors held Madrigal Pharmaceuticals (MDGL) as of Q2 2014, up from 80 in Q1 2014.
- Funds reported $213M of Madrigal Pharmaceuticals stock for Q2 2014, up 0.41% quarter-over-quarter.
- 11 funds opened new Madrigal Pharmaceuticals positions in Q2 2014 and 9 closed out, a net change of +2 holders.
- The largest Madrigal Pharmaceuticals buyer in Q2 2014 was Caxton Corporation, an estimated $5.23M added.
- The largest Madrigal Pharmaceuticals seller in Q2 2014 was Jennison Associates, an estimated $1.3M sold.
Based on aggregated 13F filings for Q2 2014.